Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive postoperative adjuvant therapy after neoadjuvant immunotherapy and radical surgery for esophageal squamous cell carcinoma
ChiCTR2300075748Phase 4Recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by Army Medical Center of PLA. Primary endpoint: Disease-free survival. Started Sep 2023; status: recruiting.
02
Drugs
camrelizumabpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300075748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075748.